Peking University People's Hospital
Department of Nephrology
The Department of Nephrology atPeking University People‘s Hospital was established in 1988. With almost 30 years’ development, wenow provide comprehensive procedures in diagnosis and treatment for patients with various kinds of acute or chronic kidney diseases.Our goal is to provide high quality medical care to patients and help them maintain high quality of life.
Our department consistsof seven parts: renal ward, outpatient clinic, hemodialysis center, peritoneal dialysis center, renal pathology laboratory, renal clinicallaboratory, and theeditorial department of the Journal of Chinese Blood Purification.
We use modern medical technology to provide a broad range ofdiagnosis and treatment services.
Pathologic diagnosis of kidney diseases
Each year, around 400 renal biopsies are performed in our department; around 800 renal biopsy samples from other hospitals in Beijing and other parts of Chinaaredelivered to our renal pathology laboratory for pathologic diagnosis. Our renal pathology team is well recognized for itsrapid reporting strategy and accurate and prompt diagnosis of many clinically complex cases, such as IgG4-relateddisease, monoclonal gammopathy of renal significance(MGRS) and so on.
We also hold clinical pathology conference(CPC) weekly. Authoritative pathologists from Peking University Renal Pathology Department areinvited to join us. After discussing cases together, appropriate pathological diagnosis can beguaranteed and patient management could be specifically individualized.
Chronic kidney disease（CKD） clinic
The number of CKD patients isincreasing rapidly, therefore we founded the CKD clinic to provide integrated treatment for them, including:
ϖ Monitoring and intervention for high risk population(e.g. individuals with diabetes, hypertension, obesity, smoking, hyperuricemia, or with advanced age) to prevent CKD.
- Slow down the progression of CKD by early intervention.
- Helping end stage renal disease (ESRD) patients choose appropriate renal replacement modalities.
- Providing patients with training program and follow-up program to assure high quality life.
The following blood purification treatment procedures are provided to treat various acute and/or chronic kidney disease:
- Peritoneal dialysis(PD)
- Continuous renal replacement therapy
- Plasma exchange
A broad range of treatment modalitiesas well as HD related surgeries and proceduresare provided. We have state-of-the-art technology both in water filtration system and in dialysis machines to ensure dialysis procedure safety.
In order to improve the quality and safety of HD, we also introduced many new technologies, including:
- Bioelectrical impedance analysis for dry weight estimation
- Vascular access function test
- Endothelial function examination
- Bacterial endotoxin quantitative test
- Rapid activated clotting time (ACT) test
HD center is now the blood purification training base for Beijing Hemodialysis Quality Control & Improvement Center (BJHDQCIC) and Chinese NursingAssociation(CNA).
Peritoneal dialysis center
Our peritoneal dialysis center has more than 180 patients so far, ranking in top three in Beijing. Several types of PD modalities areprovided to patients according to their clinical conditions.
As a kind of home care, PD patients need meticulous follow-up and monitoring. Our center evaluates every important aspectof our patients regularly, makes individualized treatment plan, offers high-qualitytraining topatients so as to help them maintain high quality life.
Compared with other international PD centers, our center has low dropout rate and low incidence of peritonitis; the control rate of anemia, nutrition, calcium and phosphorus metabolism isbetter than most other PD centers in China, and is comparable toPD centers in Japan and the US.
EDUCATION& TRAINING PROGRAM
As a department in a leading university hospital, our department has been committed to educating Peking University medical students, hospital residents and doctors from community hospitals.
Our nephrology training program provides comprehensive training in clinical nephrology and dialysis, as well as basic and clinical research. We have trained more than 100 nephrologists over the last ten years. Many of them have becomeexcellent nephrologists in their area.
In order to keep abreast ofinternational medical advancement, we also invite many world‐renowned nephrologiststo our department for academic exchanges as well as sendour staff members aboard for advanced study or attendinginternational academic conferences.
Our research activities cover a broad range of kidney disease from bench to bedside, with a specialfocus on hemodialysis and chronic kidney disease-mineral and bone disorder (CKD-MBD). A series of papers had been published. Some research projectson CKD sponsored by Peking University Clinical Research Institute and the National Health and Family Planning Commission of the People’s Republic of China are currently being carried out at our department
Our department is State Food and Drug Administration (SFDA) certificated Clinical Pharmacological Base.
Several international, multicenter, randomized clinical trials have been accomplished or are underway now, including Dialysis Outcome and Practice Pattern Study (DOPPS), A Clinical Trial of Intensive Dialysis (ACTIVE D) Study; the phase Ⅲ clinical trials for Paricalcitol, Cinacalcet, Lanthanum carbonate, AranespDarbepoetirmlfa, Roxadustat and so on.This allows us to bring the latest discoveries to our patients as quickly as possible.
Renowned Medical staff
Porf. Mei Wang is a nationally recognized expert in the field of chronic kidney disease-mineral and bone disorder(CKD-MBD). She is a council member of the Chinese Hospital Association and once served as the former president of Blood Purification Center Management Branch (BPCMB) of Chinese Hospital Association (CHA). Currently, two projects on vascular calcification associated with CKD sponsored by Peking University Clinical Research Institute are conducted under her her supervision.
Prof. Li Zuo is serving as Chair of the Department ofNephrology, andPresident of BPCMB of CHA. He is acknowledged for his research in chronic kidney disease and hemodialysis, particularly for his development of GFR estimating equation for Chinese population. Currently, he is the principal investigator of Chinese area for several international studies, including Dialysis and Practice Pattern Study (DOPPS), A Clinical Trial of Intensive Dialysis (ACTIVE D) and Asian Renal Epidemiology Cooperation (ARC).